When Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug for Pompe disease, Maze CEO Jason Coloma did not learn the news in a conference call with the French pharma giant or even an email. He found out when Sanofi issued a public statement.
Responding to the U.S. Federal Trade Commission’s move to block the licensing deal, Sanofi said it disagreed with the agency’s action, but determined that fighting it in court was “not in the best interest of patients.”
Coloma told STAT he was “personally disappointed that we didn’t get to see this through.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect